Approval · Notice of Compliance 569 · 2002
TEQUIN: Notice of Compliance 569
Issued April 16, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 569
- Date
- April 16, 2002
- Company
- Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: 5-day treatment of acute exacerbation of chronic bronchitis
- Therapeutic class
- Antibacterial agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEQUIN | Not yet assigned | — |
Medicinal ingredients
- GATIFLOXACIN 200 MG per TAB
- GATIFLOXACIN 400 MG per TAB
- GATIFLOXACIN 10 MG per ML
- GATIFLOXACIN 2 MG per ML